The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

Discussion This report of the RELIEF trial primary results indicates that for patients with generally well‐controlled PV receiving a stable dose of HC, a change in treatment to ruxolitinib monotherapy was associated with a positive trend in symptom improvement compared with those continuing on HC, although this trend was not statistically significant.

also in 11,005 other papers

Ruxolitinib was associated with a nonsignificant trend towards improved PV ‐related symptoms versus hydroxycarbamide, although an unexpectedly large proportion of patients who maintained their hydroxycarbamide dose reported symptom improvement. polycythaemia vera quality of life signs and symptoms Janus kinase hydroxycarbamide Incyte Corporation Treatment dose modifications were permitted for safety and efficacy and to optimize response for each patient.

also in 5,406 other papers